ModMed Earns Top Spot on Six Grids for its EHR and RCM Software in G2’s Spring 2024 Report
The healthcare technology leader was recognized in 28 G2 Spring 2024 Reports and earned 9 badges in G2's spring report,...
News
NextGen Healthcare to Support Ohio Nonprofit’s Delivery of Whole-Person Care for Children and Adults with Disabilities
I Am Boundless Inc. Focuses on Integration and Patient Outcomes Across 50+ Counties in the StateREMOTE-FIRST COMPANY/WORTHINGTON, Ohio--(BUSINESS WIRE)--#NextGenHealthcare--Driven by...
Smile Digital Health Launches CDA Exchange+ to Unify Patient Data for Better Accessibility and Sharing
Smile offers enhanced interoperability with their new solution that converts clinical documents to the widely used FHIR standard.TORONTO, ON /...
ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / Originally published on Bristol Myers Squibb News & PerspectivesGlobally, communities are...
Ascend Plastic Surgery Partners Announces Addition of Tallahassee Plastic Surgery Clinic to Its Distinguished Club of Visionary Surgeons
TALLAHASSEE, FL / ACCESSWIRE / May 28, 2024 / Ascend Plastic Surgery Partners (Ascend), a leading network of top-tier plastic...
Gilead Sciences Partners With White House for Early Cancer Detection Program “Biden Cancer Moonshot”
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / Gilead Sciences:In an effort to advance access to cancer prevention and...
Applied DNA Announces Pricing of $12 Million Public Offering
STONY BROOK, NY / ACCESSWIRE / May 28, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...
Sinceri Senior Living Expands Reach With Addition of the Magnolia Springs Communities
VANCOUVER, WA / ACCESSWIRE / May 28, 2024 / Sinceri Senior Living, a distinguished senior living management company, is thrilled...
Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and...
Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / May 28, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo")...
Towards a Gender Just Future
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / CARE CARE has supported 16.5 million women and girls to increase...
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
TORONTO, ON / ACCESSWIRE / May 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to...
Rehab.com Study Finds Southern States Rank Worst in Nation for Drug Abuse & Addiction
NEW YORK, NY / ACCESSWIRE / May 28, 2024 / Five Southern states rank as the worst in the nation...
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strainStudy initiated...
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics
Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and sugar moleculesNew platform capabilities extend...
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic...
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to...
Workhorse Health Introduces Innovative Mental Health Services for Ontario’s Caregivers and Their Families
TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Workhorse Health is on a mission to bridge the gap in mental health...
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in...